Date of Award
Spring 2022
Degree Name
Master of Medical Science (Physician Assistant)
Department
Physician Assistant; College of Health Sciences
First Advisor
Kimberly Erikson, MSPAS, PA-C
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death globally. China contributes to half of the global incidence of liver cancer, with about 70-85% being HCC. Definitive treatment for this condition would be surgical resection with liver transplant but for obvious reasons, the majority of affected patients are unable to meet the necessary criteria. Sorafenib is a form of chemotherapy that has been the mainstay treatment of HCC since its approval in 2007. More recently, the combination of Bevacizumab and Atezolizumab has shown greater efficacy in the treatment of unresectable HCC. Additionally, this new combination therapy shows favorable results in terms of long-term adverse effects. However, on an economic standpoint, the cost of long-term therapy may hinder its progression towards mainstay treatment.
Recommended Citation
Lee, Joon, "In patients with hepatocellular carcinoma (HCC) (P), is Bevacizumab with Atezolizumab (I) more effective than Sorafenib (C) in long-term clinical prognosis (O)?" (2022). Capstone Showcase. 103.
https://scholarworks.arcadia.edu/showcase/2022/pa/103
In patients with hepatocellular carcinoma (HCC) (P), is Bevacizumab with Atezolizumab (I) more effective than Sorafenib (C) in long-term clinical prognosis (O)?
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death globally. China contributes to half of the global incidence of liver cancer, with about 70-85% being HCC. Definitive treatment for this condition would be surgical resection with liver transplant but for obvious reasons, the majority of affected patients are unable to meet the necessary criteria. Sorafenib is a form of chemotherapy that has been the mainstay treatment of HCC since its approval in 2007. More recently, the combination of Bevacizumab and Atezolizumab has shown greater efficacy in the treatment of unresectable HCC. Additionally, this new combination therapy shows favorable results in terms of long-term adverse effects. However, on an economic standpoint, the cost of long-term therapy may hinder its progression towards mainstay treatment.